About 200 reports

  • Dementia
  • DEMENTIA

About Dementia and Movement Disorder Treatment Dementia is a collective term for disorders characterized by progressive degeneration of the brain. It impairs memory and affects behavioral, emotional, and cognitive abilities. The neuronal death or neuronal malfunction associated with the disorder manifests as shifts in mood and...

  • Dementia
  • Allergan plc
  • Eisai Co., Ltd.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • United States Dementia Market Outlook
  • Global Dementia Disease Market Size , By

Executive Summary Progressive numbers of neurological disorders along with escalating demand for drugs to control of Alzheimer Disease. The Global Alzheimer’s Market is growing at a moderate rate over last five years on account of rising expenditure on health care especially neurological disorders among ageing population...

  • Dementia
  • Axovant Sciences Ltd.
  • Biotie Therapies Corp.
  • Novartis AG
  • Pfizer Inc.

Vascular Dementia - Epidemiology Forecast to 2027 ##.

  • Dementia
  • France
  • Germany
  • Italy
  • Spain
  • SUB-TYPE OF CO-MORBID DEMENTIA, TOTAL (000S)
  • USA PREVALENCE OF LEWY BODY DEMENTIA BY 5-YR AGE COHORT, FEMALES (000S)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative dementia, accounting for approximately a third of all dementias. The presence of Lewy bodies in the brain is linked to low levels of...

  • Dementia
  • United States
  • Forecast
  • FEATURES OF VASCULAR DEMENTIA PATIENTS
  • Prevalence of Vascular Dementia, females (000s)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Vascular Dementia in 13 Major Markets Vascular Dementia (VaD) is the second most common form of dementia after Alzheimer disease. It is also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI), and is caused by issues with blood supply...

  • Dementia
  • Mental Health
  • Pathology
  • East Asia

Drug A: Company ## ##. ##. ##.

  • Dementia
  • Mental Health
  • United States
  • Market Shares
  • Alzheimer's disease in 2016, and the patients diagnosed with Alzheimer's or another dementia
  • Alzheimer's and other dementias, including blood vessel damage and genetic risk

Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted...

  • Dementia
  • World
  • Biogen Idec Inc.
  • Eisai Co., Ltd.
  • Roche Group
  • DSM-IV Criteria for the Diagnosis of Dementia
  • 4.1 BIBLIOGRAPHY

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026 Summary Alzheimer’s disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive...

  • Dementia
  • Spain
  • United States
  • World
  • Forecast
  • EXELON
  • EISAI PHARMACEUTICALS

You can easily book an appointment with one online.

  • Dementia
  • Forecast
  • Allergan plc
  • Eisai Co., Ltd.
  • Novartis AG

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026 ##.

  • Dementia
  • Therapy
  • World
  • 6.1.1 PROBABLE AD DEMENTIA
  • DSM-IV CRITERIA FOR THE DIAGNOSIS OF DEMENTIA

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2026 Summary Alzheimer’s disease (AD) is a looming endangerment to global health, and a threat to the world economy. One in every three seniors in the US dies with AD or another form of dementia. It is the sixth leading...

  • Dementia
  • Allergan plc
  • Biogen Idec Inc.
  • Eisai Co., Ltd.
  • Novartis AG

Dementia is one of the major causes of disability among the elderly population.

  • Dementia
  • Therapy
  • United States
  • World
  • Company Financials
  • 1.1.2 Types of Dementia
  • 2.1 Global Dementia Market

Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such...

  • Dementia
  • Eli Lilly & Co.
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 10.1.4 Types of Dementia
  • Untitled

About neurodegenerative diseases According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely...

  • Dementia
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.
  • NEURODEGENERATIVE DISORDERS THERAPEUTICS MARKET, COMORBIDITIES ASSOCIATED WITH
  • NEURODEGENERATIVE DISORDERS THERAPEUTICS MARKET, SYMPTOMS OF AD, PD, HD, ALS

Alzheimer' s & Dementia; ##(##): ##-## Inglese M (2006).

  • Dementia
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • OCT 09, 2017: KAROLINSKA INSTITUTET: SAFE TO TREAT DEMENTIA PATIENTS WITH CLOT-BUSTING DRUGS
  • OCT 24, 2017: BLOOD-THINNING DRUGS APPEAR TO PROTECT AGAINST DEMENTIA AS WELL AS STROKE IN AF PATIENTS

Summary Karolinska Institutet (KI) is a medical university that offers education services.The university provides education and research in the fields of medicine and health sciences. Its education courses include audiology, biomedicine, biomedical lab science, dental hygiene, medicine, nursing, occupational therapy...

  • Cancer
  • Dementia
  • Sweden
  • Karolinska Institutet Holding
  • Takeda Pharmaceutical Company Limited
  • 5.1.1 PROBABLE AD DEMENTIA
  • DSM-III-R CRITERIA FOR THE DIAGNOSIS OF DEMENTIA

PharmaPoint: Alzheimer’s Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update Summary Alzheimer’s Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances...

  • Dementia
  • Market Size
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Roche Group

According to Alzheimer’s Association, one in every ## adults in the United States dies with Alzheimer’s or another dementia.

  • Dementia
  • Mental Health
  • Therapy
  • North America
  • Market Size

EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026 ##.

  • Dementia
  • Mental Health
  • Therapy
  • Europe
  • Market Size
  • CAUSE OF THE DISEASE
  • INTRODUCTION

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disorder. It is the leading cause of dementia. Alzheimer’s is associated with the increase of beta amyloid and tau proteins in the brains of affected patients....

  • Dementia
  • Mental Health
  • Pathology
  • 7.2.1 ALZHEIMER'S DISEASES
  • 7.1.2.2 OTHERS

Genes play an important role in the development of diseases, such as dementia and Alzheimer' s.

  • Dementia
  • North America
  • United States
  • World
  • Forecast

Alzheimer's disease

4546 5000 3864
  • DEMENTIA CAREGIVER TASKS
  • DSM-IV-TR DIAGNOSTIC CRITERIA FOR 294.1X DEMENTIA OF THE ALZHEIMER'S TYPE

Amyloid-targeting immunotherapies may create a $10bn opportunity within the Alzheimer’s disease market. This report addresses the following questions: - How will the approval of immunotherapies affect Alzheimer’s disease treatment dynamics? - Which patient subgroups and drug class will have the largest impact on Alzheimer’s...

  • Dementia
  • East Asia
  • European Union
  • Japan
  • United States

ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026 ##.

  • Dementia
  • Therapy
  • APAC
  • Market Size
  • Nicergoline Major Producer and Their Market Share
  • Overview

This study focuses on China’s Alzheimer Disease Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major...

  • Dementia
  • China
  • Demand
  • Janssen Biotech, Inc.
  • Xian-Janssen Pharmaceutical Ltd.
  • AD Market, Global Deterioration Scale for AD
  • AD Market, Symptoms of Mid Cognitive Impairment

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Disease Modifying Therapies Summary Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional...

  • Dementia
  • East Asia
  • World
  • Forecast
  • Biogen Idec Inc.
  • Nicergoline Major Producer and Their Market Share
  • Overview

China’s demand for Alzheimer Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...

  • Dementia
  • China
  • Demand
  • Novartis AG
  • Shandong Qilu Pharmaceutical Co., Ltd
  • 2.5 Pathophysiology
  • 2.1 Disease Introduction

Stages ##-## are pre-dementia stages, with dementia beginning at stage four.

  • Dementia
  • World
  • Forecast
  • Market Size
  • Eisai Co., Ltd.

Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies ##.

  • Dementia
  • Diagnostics
  • Mental Health
  • World
  • Market Size
  • Lewy body Dementia - Dormant Projects
  • Lewy body Dementia - Therapeutics Assessment

Lewy body Dementia - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Lewy body Dementia - Pipeline Review, H2 2016’, provides an overview of the Lewy body Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lewy body Dementia, complete...

  • Dementia
  • United States
  • World
  • Product Initiative
  • Axovant Sciences Ltd.
  • Prevalence of dementia by type in sporadic ALS, total (000s)
  • Prevalence of dementia in sporadic ALS patients, total (000s)

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Amyotrophic Lateral Sclerosis in 9 Major Markets Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig’s disease or motor neuron disease, is a is a rapidly progressive, fatal neurological disease in which upper and lower motor neurons degrade and eventually...

  • Dementia
  • Mental Health